Iqymune

Human normal immunoglobulin, the active ingredient in Iqymune, is an immunoglobulin presented as a sterile solution for injection for intravenous use. It provides passive immunity and is indicated for primary and secondary immunodeficiency diseases, idiopathic thrombocytopenic purpura, Kawasaki disease, and chronic inflammatory demyelinating polyneuropathy in appropriate patients.

GNH USA supplies Iqymune as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with capabilities for cold‑chain logistics and regulatory support and ensuring product integrity.

Iqymune, a human normal immunoglobulin, is used to replace deficient antibodies in various immune‑mediated conditions.

Primary immunodeficiency diseases: provides IgG replacement to reduce infection frequency and severity. Secondary immunodeficiency: restores antibody levels in patients with acquired immune compromise. Idiopathic thrombocytopenic purpura: raises platelet counts by modulating auto‑immune destruction. Kawasaki disease: reduces inflammation and coronary artery complications in acute phases. Chronic inflammatory demyelinating polyneuropathy: improves muscle strength and functional recovery by modulating immune attack on nerves.

Adverse reactions to Iqymune may range from mild to severe and are reported following intravenous administration.

Common Side Effects: - Headache: transient headache occurring during or after infusion. - Fever and chills: mild to moderate temperature rise with shaking. - Nausea or vomiting: gastrointestinal discomfort during infusion. - Fatigue: temporary tiredness post‑administration.

Serious or Rare Side Effects: - Aseptic meningitis: inflammation of meninges without infection. - Thromboembolic events: clot formation leading to vascular occlusion. - Acute renal failure: sudden loss of kidney function, especially with high infusion rates. - Anaphylaxis: severe allergic reaction requiring immediate medical intervention.

Prior to initiating Iqymune therapy, several precautions should be observed to minimize risk. Screen for IgA deficiency: assess risk of anaphylaxis in IgA‑deficient patients. Monitor renal function: avoid high infusion rates in patients with renal impairment. Assess thrombotic risk: use caution in individuals with cardiovascular disease or hypercoagulable states. Observe for hemolysis: check hemoglobin levels in patients with blood‑group antibodies. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iqymune can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Live attenuated vaccines: may reduce vaccine efficacy; avoid concurrent administration. - Cytotoxic chemotherapy agents: increased risk of renal toxicity when combined.

Moderate Interactions (Monitor Closely): - Warfarin: immunoglobulin may alter INR; monitor coagulation parameters. - Rituximab: may diminish response to IVIG; assess clinical effect. - Inactivated vaccines: possible reduced immunogenicity; evaluate antibody titers after vaccination.